TBG Diagnostics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Greenslopes Australia (1989)
Status: No NME R&D (1989)

Organization Overview

First Clinical Trial
None
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
None

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (1)

Key: TBG Diagnostics (0) Acquired (1)

pi-88 (6 trials)

Drugs in Phase 2 Trials (4)

Key: TBG Diagnostics (0) Acquired (4)

cgc-11047 (5 trials)

dacarbazine (dtic-dome) (1 trial)

docetaxel (taxotere) (3 trials)

prednisone (meticorten) (1 trial)

Drugs in Phase 1 Trials (8)

Key: TBG Diagnostics (0) Acquired (8)

bevacizumab (avastin) (1 trial)

cisplatin (platinol) (1 trial)

erlotinib (tarceva) (1 trial)

fluorouracil (efudex) (1 trial)

gemcitabine (gemzar) (1 trial)

leucovorin (1 trial)

pg545 (2 trials)

sunitinib (sutent) (1 trial)

Indications

Overview

  • Highest Phase: None
  • # of Trials: 13
  • # of Trial APIs: 13